Patent application number | Description | Published |
20150057346 | METHODS OF MAINTAINING INTRAMUSCULAR MYOGLOBIN LEVELS, MAINTAINING MAXIMAL AEROBIC CAPACITY, AND ENHANCING THE OXIDATIVE CAPACITY OF MUSCLE IN A SUBJECT - Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject in need thereof are provided. Generally, the methods include administering an effective amount of β-hydroxy-β-methylbutyrate to the subject. The β-hydroxy-β-methylbutyrate may be administered as part of a nutritional composition. | 02-26-2015 |
20150057350 | FIBROSIS BIOMARKERS AND METHODS OF USING SAME - Methods and systems for using fibrosis biomarkers associated with a prolonged period of physical inactivity are provided. Also provided is a method of reducing the effect of prolonged physical inactivity on the development of fibrosis in a subject who is experiencing or is expected to experience prolonged physical inactivity in the near future by administering a therapeutically effective amount of a leucine metabolite (e.g., β-hydroxy-β-methylbutyric acid (HMB)) to the subject. | 02-26-2015 |
20150119339 | USE OF HMB TO IMPROVE HEALTH OUTCOMES FOR HOSPITALIZED PATIENTS - A method of care is described that includes administering an effective amount of β-hydroxy-β-methylbutyrate (HMB) to an adult or elderly patient to decrease the risk of an adverse health event during or subsequent to hospitalization of the patient. | 04-30-2015 |
20160022617 | TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH PROLONGED PHYSICAL INACTIVITY - Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future. | 01-28-2016 |
20160106131 | USE OF HMB TO IMPROVE QUALITY OF LIFE FOR HOSPITALIZED PATIENTS - A method of care is described that includes administering an effective amount of β-hydroxy-β-methylbutyrate (HMB) to an adult or elderly patient to improve the patient's quality of life during or after hospitalization of the patient. The improved quality of life may encompass the general health, physical health, or mental health of the patient. | 04-21-2016 |
Patent application number | Description | Published |
20140296445 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow - A method for preparing a coupled polymer, the method comprising the steps of: (i) polymerizing monomers to form a reactive polymer, and (ii) reacting the reactive polymer with a glycidic ester. | 10-02-2014 |
20140303327 | Process For Producing Polydienes - A method for producing a polydiene, the method comprising the steps of: (i) forming an active catalyst by combining a lanthanide-containing compound, an alkylating agent, and a halogen source in the substantial absence of a sulfone, a sulfoxide, and a phosphine oxide; and (ii) polymerizing conjugated diene monomer in the presence of the active catalyst and a polymerization modulator selected from the group consisting of a sulfone, a sulfoxide, and a phosphine oxide. | 10-09-2014 |
20150299350 | Processes For The Preparation Of High-Cis Polydienes - Disclosed herein are solution polymerization processes for producing a high-cis polydiene. The processes include polymerizing at least one conjugated diene monomer in an organic solvent in the presence of at least one thiol compound and a lanthanide-based catalyst composition to produce a polydiene having a cis-1,4-linkage content of 90-99%. The at least one thiol compound is represented by the general formula R—S—H, where R is a hydrocarbyl group or a substituted hydrocarbyl group. The lanthanide-based catalyst composition comprises (a) a lanthanide compound, (b) an alkylating agent, and (c) a halogen source, where (c) may optionally be provided by (a), (b), or both (a) and (b). The molar ratio of the at least one thiol compound to the lanthanide compound used in the polymerization process ranges from 0.01:1 to 100:1. Improved solution polymerization processes regarding the same are also disclosed herein. | 10-22-2015 |